Zheng Xiaodan, Zheng Yuanyuan, Zhang Yanlin, Xie Jianlan, Teng Xiaojing, Bi Kuo, Sun Lan, Huang Xiaowen, Jin Mulan, Zhou Xiaoge
Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Infect Agent Cancer. 2025 Jan 22;20(1):3. doi: 10.1186/s13027-024-00627-x.
The differential diagnosis between adult systemic EBV-positive T-cell lymphoproliferative disorders (EBV T-LPD) and angioimmunoblastic T-cell lymphoma (AITL) with multiple EBV infections is difficult, and distinguishing between the two has become a diagnostic challenge for pathologists. Given that the clinical treatment plans are different, an accurate diagnosis is a prerequisite to ensure effective treatment, therefore, it is extremely necessary and meaningful to find effective pathological indicators for distinguishing between two diseases.
We present a retrospective study comparing 7 cases of adult EBV T-LPD and 16 cases of AITL with multiple EBV infections diagnosed at our institution from 2017 to 2022. Differences in immunophenotype, type of EBV-infected cells, clonality and gene mutations between the two groups of cases were compared by immunohistochemical staining, double-label staining, TCR gene rearrangement and next-generation sequencing analysis.
7 cases of adult EBV T-LPD: all cases had no more than 1 T follicular helper (THF) marker was expressed, and there were significantly more EBER+/CD3 + cells than EBER+/CD20 + cells; 5 cases had mutation detection results, in which only 1 had the characteristic KMT2D mutation, 2 had TET2 mutations, and no common mutations such as DDX3X were detected.16 cases of AITL with multiple EBV infections: all cases were found to express at least 2 TFH markers, with 87% of them expressing at least 3 TFH markers., and had significantly more EBER+/CD20 + cells than EBER+/CD3 + cells; 4 cases had mutation test results, with mutated high-frequency genes being TET2 (100%, and all of them had 2 or more TET2 mutations) and RHOA G17V (100%), DNMT3A mutation occurred in 2 cases (50%), and IDH2 R172 mutation occurred in 1 case (25%).
We found that the expression pattern of TFH markers, the types of cells predominantly infected by EBV and the different mutations can all be used as effective pathological indicators for distinguishing between two diseases.
成人系统性EB病毒阳性T细胞淋巴增殖性疾病(EBV T-LPD)与伴有多重EB病毒感染的血管免疫母细胞性T细胞淋巴瘤(AITL)的鉴别诊断较为困难,对两者进行区分已成为病理学家面临的一项诊断挑战。鉴于临床治疗方案不同,准确诊断是确保有效治疗的前提条件,因此,寻找区分这两种疾病的有效病理指标极具必要性和意义。
我们开展了一项回顾性研究,比较了2017年至2022年在我院诊断的7例成人EBV T-LPD和16例伴有多重EB病毒感染的AITL。通过免疫组织化学染色、双标记染色、TCR基因重排和二代测序分析,比较两组病例在免疫表型、EB病毒感染细胞类型、克隆性和基因突变方面的差异。
7例成人EBV T-LPD:所有病例表达的T滤泡辅助细胞(THF)标志物均不超过1种,EBER+/CD3 +细胞明显多于EBER+/CD20 +细胞;5例有突变检测结果,其中仅1例有特征性的KMT2D突变,2例有TET2突变,未检测到DDX3X等常见突变。16例伴有多重EB病毒感染的AITL:所有病例均至少表达2种TFH标志物,其中87%至少表达3种TFH标志物,且EBER+/CD20 +细胞明显多于EBER+/CD3 +细胞;4例有突变检测结果,高频突变基因有TET2(100%,且均有2个或以上TET2突变)和RHOA G17V(100%),2例(50%)发生DNMT3A突变,1例(25%)发生IDH2 R172突变。
我们发现TFH标志物的表达模式、主要被EB病毒感染的细胞类型以及不同的突变均可作为区分这两种疾病的有效病理指标。